In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of $214.00. The company’s shares closed last Friday ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened today at $183.18. Leverage the power of TipRanks ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

After hours: 7:54:48 p.m. EST ...

After hours: 7:59:33 pm GMT-5 ...